Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study. [electronic resource]
Producer: 20170606Description: 1011-7 p. digitalISSN:- 1346-8138
- Adult
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Arthralgia -- chemically induced
- Diabetes Mellitus -- chemically induced
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Humans
- Interleukin-17 -- antagonists & inhibitors
- Japan
- Male
- Middle Aged
- Nasopharyngitis -- chemically induced
- Practice Guidelines as Topic
- Psoriasis -- drug therapy
- Severity of Illness Index
- Treatment Outcome
- Urticaria -- chemically induced
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.